Covered recipient · General Payments record
TESS BOLLETTA
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2022–2024
$1,503.11
- Reported across 82 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $300.83 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $98.59 | 4 |
| ABBVIE INC. | $58.40 | 3 |
| Amgen Inc. | $28.53 | 2 |
| Astellas Pharma US Inc | $26.10 | 1 |
| Ultragenyx Pharmaceutical Inc. | $25.09 | 1 |
| IRONSHORE PHARMACEUTICALS INC. | $24.33 | 1 |
| Janssen Pharmaceuticals, Inc | $15.68 | 1 |
| Vanda Pharmaceuticals Inc. | $13.78 | 1 |
| Corium, Inc. | $10.33 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.65 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106791622 | CMS |
| ABBVIE INC. | $16.62 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106791626 | CMS |
| ABBVIE INC. | $17.13 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106791630 | CMS |
| Amgen Inc. | $15.34 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117510396 | CMS |
| Amgen Inc. | $13.19 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117510398 | CMS |
| Astellas Pharma US Inc | $26.10 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139488016 | CMS |
| Corium, LLC | $10.33 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100155479 | CMS |
| IRONSHORE PHARMACEUTICALS INC. | $24.33 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146265367 | CMS |
| Janssen Pharmaceuticals, Inc | $15.68 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078181441 | CMS |
| Lilly USA, LLC | $19.84 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135964506 | CMS |
| Lilly USA, LLC | $26.61 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135962083 | CMS |
| Lilly USA, LLC | $25.24 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135968640 | CMS |
| Lilly USA, LLC | $26.90 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135895587 | CMS |
| Ultragenyx Pharmaceutical Inc. | $25.09 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153281876 | CMS |
| Vanda Pharmaceuticals Inc. | $13.78 | 02/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133932170 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.